UNSPSC 51343814: Efavirenz/lamivudine/tenofovir DF

This classification denotes a combination drug for treatment of HIV. The first component, EFAVIRENZ, has US FDA Unique Ingredient Identifier of JE6H2O27P8. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.

UNSPSC 51343814 Efavirenz/lamivudine/tenofovir DF is a Commodity code encompassing antiretroviral combination pharmaceuticals for treatment of HIV. State and local governments procure this drug through health departments, county health systems, correctional facilities, and public clinics, typically as part of formulary contracts or direct purchase agreements for patient treatment programs. The recent solicitation record shows minimal activity tagged directly to this code—the most recent opportunities posted in the past six months include a June 2026 Seminole County, Florida IFB for naloxone and drug deactivation systems, a June 2026 Tucson Fire Department RFP for BLS/ALS pharmaceuticals and medical supplies, a January 2026 Little Rock Fire Department ITQ for medical oxygen cylinder rental, and a January 2026 Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products. None of these solicitations explicitly name efavirenz/lamivudine/tenofovir DF or antiretroviral medications as a line item. The code's nominal scope—a fixed-dose HIV treatment combination—does not align with the emergency medical supply, oxygen rental, naloxone, or broad-spectrum generic pharmaceutical procurements that dominate the recent opportunities block.

The geographic spread of procurement activity in the source spans Florida (Seminole County, Pinellas County), Arizona (Tucson), Arkansas (Little Rock), Texas (Williamson County), and multi-state cooperative purchasing through Minnesota MMCAP. However, none of these represent active demand for efavirenz/lamivudine/tenofovir DF specifically. State and local health departments and correctional agencies are the typical issuing bodies for antiretroviral drugs, but this source contains no recent RFP, RFQ, IFB, or ITB activity for HIV treatment pharmaceuticals. The code shows little relevant recent activity; the recent opportunities have been tagged to this UNSPSC category by agencies but do not reflect procurement of the product the code describes.